Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17342249 | 0.93 | ESR1 (0.34) | ESR1ESR2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL17383975 | 0.87 | GPR174 (0.33) | ESR1ESR2ALDH1A1 | |
| SCHEMBL18788353 | 0.76 | TSHR (0.38) | CYP3A4TSHRSMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL17345798 | 0.71 | CALM1 (0.44) | CYP3A4CYP2C19IDH1TSHRCALM1 | |
| SCHEMBL11030098 | 0.70 | ESR1 (0.50) | ESR1ESR2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL17342250 | 0.68 | ALDH1A1 (0.44) | CYP3A4CYP2C19IDH1TSHRCALM1 | |
| SCHEMBL20127054 | 0.67 | PTPN1 (0.34) | CALM1 | |
| SCHEMBL3304087 | 0.66 | CALM1 (0.55) | ESR1ESR2KDM4ECYP3A4CYP2C19 | |
| SCHEMBL18788349 | 0.65 | CYP1A2 (0.39) | ESR1ESR2CYP3A4TSHRSMN1; SMN2 | |
| Styrene SCHEMBL9627821 | 0.64 | ALDH1A1 (0.39) | ESR1ESR2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472302-B2 | Ligand compound, organic chromium compound, catalyst system for oligomerization of olefins, and method for oligomerization of olefins using the catalyst system | LG CHEM, LTD. (KR) | 2019-11-12 | — | — | US | disclosed |
| US-20170260305-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME | LG CHEM, LTD. (KR) | 2017-09-14 | — | — | US | disclosed |
| US-9562062-B2 | Ligand compound, organic chromium compound, catalyst system for ethylene oligomerization, and method for ethylene oligomerization using the same | LG CHEM, LTD (KR) | 2017-02-07 | — | — | US | disclosed |
| US-20170029346-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZATION OF OLEFINS, AND METHOD FOR OLIGOMERIZATION OF OLEFINS USING THE CATALYST SYSTEM (AS AMENDED) | LG CHEM, LTD. (KR) | 2017-02-02 | — | — | US | disclosed |
| US-20150361118-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME | LG CHEM, LTD. (KR) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029346-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND, CATALYST SYSTEM FOR OLIGOMERIZATION OF OLEFINS, AND METHOD FOR OLIGOMERIZATION OF OLEFINS USING THE CATALYST SYSTEM (AS AMENDED) | OXER1, OSTC, ORC3 | ESR1 732/4885ESR2 1046/4885KDM4E 4167/4885 |
| US-20170260305-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME | OXER1, OSTC, OCIAD1 | ESR1 571/4885ESR2 740/4885KDM4E 4712/4885 |
| US-10472302-B2 | Ligand compound, organic chromium compound, catalyst system for oligomerization of olefins, and method for oligomerization of olefins using the catalyst system | OXER1, OSTC, ORC3 | ESR1 705/4885ESR2 990/4885KDM4E 4217/4885 |
| US-20150361118-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME | OXER1, OSTC, OR51E2 | ESR1 25/4885ESR2 74/4885KDM4E 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.